메뉴 건너뛰기




Volumn 99, Issue 8, 2007, Pages 628-638

Expression of p95HER2, a truncated form of the HER2 receptor, and response to Anti-HER2 therapies in breast cancer

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; HYDROXYPROPYLMETHYLCELLULOSE; LAPATINIB; MITOGEN ACTIVATED PROTEIN KINASE; NAVELBINE; PARAFFIN; PHOSPHOTRANSFERASE; POLYSORBATE 80; PROTEIN KINASE B; PROTEIN TYROSINE KINASE INHIBITOR; STEROID; TAXANE DERIVATIVE; TRASTUZUMAB; ANTINEOPLASTIC AGENT; COMPLEMENTARY DNA; MONOCLONAL ANTIBODY; QUINAZOLINE DERIVATIVE;

EID: 34247588567     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djk134     Document Type: Article
Times cited : (696)

References (38)
  • 1
    • 5644252971 scopus 로고    scopus 로고
    • Molecular approach to breast cancer treatment
    • Yarden Y, Baselga J, Miles D. Molecular approach to breast cancer treatment. Semin Oncol 2004;31 Suppl 10:6-13.
    • (2004) Semin Oncol , vol.31 , Issue.SUPPL. 10 , pp. 6-13
    • Yarden, Y.1    Baselga, J.2    Miles, D.3
  • 2
    • 18344390418 scopus 로고    scopus 로고
    • ErbB receptors and cancer: The complexity of targeted inhibitors
    • Hynes NE, Lane HA. ErbB receptors and cancer: The complexity of targeted inhibitors. Nat Rev Cancer 2005;5:341.
    • (2005) Nat Rev Cancer , vol.5 , pp. 341
    • Hynes, N.E.1    Lane, H.A.2
  • 3
    • 37049183697 scopus 로고
    • Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene
    • Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987;235:177-82.
    • (1987) Science , vol.235 , pp. 177-182
    • Slamon, D.J.1    Clark, G.M.2    Wong, S.G.3    Levin, W.J.4    Ullrich, A.5    McGuire, W.L.6
  • 5
    • 0024478054 scopus 로고
    • p185HER-2 monoclonal antibody has antiproliferative effects in vitro and sensitizes human breast tumor cells to tumor necrosis factor
    • Hudziak RM, Lewis GD, Winget M, Fendly BM, Shepard HM, Ullrich A. p185HER-2 monoclonal antibody has antiproliferative effects in vitro and sensitizes human breast tumor cells to tumor necrosis factor. Mol Cell Biol 1989;9:1165-72.
    • (1989) Mol Cell Biol , vol.9 , pp. 1165-1172
    • Hudziak, R.M.1    Lewis, G.D.2    Winget, M.3    Fendly, B.M.4    Shepard, H.M.5    Ullrich, A.6
  • 8
    • 0036467826 scopus 로고    scopus 로고
    • Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER-2-overexpressing metastatic breast cancer
    • Vogel CL, Cobleigh MA, Tripathy D, Gutheil JC, Harris LN, Fehrenbacher L, et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER-2-overexpressing metastatic breast cancer. J Clin Oncol 2002;20:719-26.
    • (2002) J Clin Oncol , vol.20 , pp. 719-726
    • Vogel, C.L.1    Cobleigh, M.A.2    Tripathy, D.3    Gutheil, J.C.4    Harris, L.N.5    Fehrenbacher, L.6
  • 10
    • 0032850677 scopus 로고    scopus 로고
    • Multinational study of the efficacy and safety of humanized anti-HER-2 monoclonal antibody in women who have HER-2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease
    • Cobleigh MA, Vogel CL, Tripathy D, Robert NJ, Scholl S, Fehrenbacher L, et al. Multinational study of the efficacy and safety of humanized anti-HER-2 monoclonal antibody in women who have HER-2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 1999; 17:2639-48.
    • (1999) J Clin Oncol , vol.17 , pp. 2639-2648
    • Cobleigh, M.A.1    Vogel, C.L.2    Tripathy, D.3    Robert, N.J.4    Scholl, S.5    Fehrenbacher, L.6
  • 11
    • 17144371333 scopus 로고    scopus 로고
    • Phase II study of efficacy, safety, and pharmacokinetics of trastuzumab monotherapy administered on a 3-weekly schedule
    • Baselga J, Carbonell X, Castaneda-Soto NJ, Clemens M, Green M, Harvey V, et al. Phase II study of efficacy, safety, and pharmacokinetics of trastuzumab monotherapy administered on a 3-weekly schedule. J Clin Oncol 2005;23:2162-71.
    • (2005) J Clin Oncol , vol.23 , pp. 2162-2171
    • Baselga, J.1    Carbonell, X.2    Castaneda-Soto, N.J.3    Clemens, M.4    Green, M.5    Harvey, V.6
  • 12
    • 0035869407 scopus 로고    scopus 로고
    • Use of chemotherapy plus a monoclonal antibody against HER-2 for metastatic breast cancer that overexpresses HER-2
    • Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, et al. Use of chemotherapy plus a monoclonal antibody against HER-2 for metastatic breast cancer that overexpresses HER-2. N Engl J Med 2001;344:783-92.
    • (2001) N Engl J Med , vol.344 , pp. 783-792
    • Slamon, D.J.1    Leyland-Jones, B.2    Shak, S.3    Fuchs, H.4    Paton, V.5    Bajamonde, A.6
  • 13
    • 22344446208 scopus 로고    scopus 로고
    • Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: The M77001 study group
    • Marty M, Cognetti F, Maraninchi D, Snyder R, Mauriac L, Tubiana-Hulin M, et al. Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: The M77001 study group. J Clin Oncol 2005;23:4265-74.
    • (2005) J Clin Oncol , vol.23 , pp. 4265-4274
    • Marty, M.1    Cognetti, F.2    Maraninchi, D.3    Snyder, R.4    Mauriac, L.5    Tubiana-Hulin, M.6
  • 16
    • 33645720799 scopus 로고    scopus 로고
    • Phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (ACT) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (ACTH) with docetaxel, carboplatin and trastuzumab (TCH) in HER-2 positive early breast cancer patients: BCIRG 006 study
    • December 8-11, ABstract
    • Slamon D, Eiermann W, Robert N, Pienkowski T, Martin M, Pawlicki M, et al. Phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (ACT) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (ACTH) with docetaxel, carboplatin and trastuzumab (TCH) in HER-2 positive early breast cancer patients: BCIRG 006 study. 28th Annual San Antonio Breast Cancer Symposium (December 8-11, 2005):ABstract 1.
    • (2005) 28th Annual San Antonio Breast Cancer Symposium , pp. 1
    • Slamon, D.1    Eiermann, W.2    Robert, N.3    Pienkowski, T.4    Martin, M.5    Pawlicki, M.6
  • 17
    • 5144226211 scopus 로고    scopus 로고
    • PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients
    • Nagata Y, Lan KH, Zhou X, Tan M, Esteva FJ, Sahin AA, et al. PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell 2004;6:117-27.
    • (2004) Cancer Cell , vol.6 , pp. 117-127
    • Nagata, Y.1    Lan, K.H.2    Zhou, X.3    Tan, M.4    Esteva, F.J.5    Sahin, A.A.6
  • 18
    • 0035915421 scopus 로고    scopus 로고
    • Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (Herceptin)
    • Lu Y, Zi Y, Zhao Y, Mascarenhas D, Pollak M. Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (Herceptin). J Natl Cancer Inst 2001;93:1852-7.
    • (2001) J Natl Cancer Inst , vol.93 , pp. 1852-1857
    • Lu, Y.1    Zi, Y.2    Zhao, Y.3    Mascarenhas, D.4    Pollak, M.5
  • 19
    • 0036187710 scopus 로고    scopus 로고
    • NH(2)-terminal truncated HER-2 protein but not full-length receptor is associated with nodal metastasis in human breast cancer
    • Molina MA, Saez R, Ramsey EE, Garcia-Barchino MJ, Rojo F, Evans AJ, et al. NH(2)-terminal truncated HER-2 protein but not full-length receptor is associated with nodal metastasis in human breast cancer. Clin Cancer Res 2002;8:347-53.
    • (2002) Clin Cancer Res , vol.8 , pp. 347-353
    • Molina, M.A.1    Saez, R.2    Ramsey, E.E.3    Garcia-Barchino, M.J.4    Rojo, F.5    Evans, A.J.6
  • 20
    • 0032532950 scopus 로고    scopus 로고
    • NH2-terminally truncated HER-2/neu protein: Relationship with shedding of the extracellular domain and with prognostic factors in breast cancer
    • Christianson TA, Doherty JK, Lin YJ, Ramsey EE, Holmes R, Keenan EJ, et al. NH2-terminally truncated HER-2/neu protein: Relationship with shedding of the extracellular domain and with prognostic factors in breast cancer. Cancer Res 1998;58:5123-9.
    • (1998) Cancer Res , vol.58 , pp. 5123-5129
    • Christianson, T.A.1    Doherty, J.K.2    Lin, Y.J.3    Ramsey, E.E.4    Holmes, R.5    Keenan, E.J.6
  • 21
    • 0033559210 scopus 로고    scopus 로고
    • Cleavage of the HER-2 ectodomain is a pervanadate-activable process that is inhibited by the tissue inhibitor of metalloproteases-1 in breast cancer cells
    • Codony-Servat J, Albanell J, Lopez-Talavera JC, Arribas J, Baselga J. Cleavage of the HER-2 ectodomain is a pervanadate-activable process that is inhibited by the tissue inhibitor of metalloproteases-1 in breast cancer cells. Cancer Res 1999;59:1196-201.
    • (1999) Cancer Res , vol.59 , pp. 1196-1201
    • Codony-Servat, J.1    Albanell, J.2    Lopez-Talavera, J.C.3    Arribas, J.4    Baselga, J.5
  • 22
    • 33746290773 scopus 로고    scopus 로고
    • Biosynthesis of tumorigenic HER-2 C-terminal fragments by alternative initiation of translation
    • Anido J, Scaltriti M, Bech Serra JJ, Santiago Josefat B, Todo, FR, Baselga J, et al. Biosynthesis of tumorigenic HER-2 C-terminal fragments by alternative initiation of translation. EMBO J 2006;25:3234-44.
    • (2006) EMBO J , vol.25 , pp. 3234-3244
    • Anido, J.1    Scaltriti, M.2    Bech Serra, J.J.3    Santiago Josefat, B.4    Todo, F.R.5    Baselga, J.6
  • 23
    • 4644289313 scopus 로고    scopus 로고
    • A unique structure for epidermal growth factor receptor bound to GW572016 (Lapatinib): Relationships among protein conformation, inhibitor off-rate, and receptor activity in tumor cells
    • Wood ER, Truesdale AT, McDonald OB, Yuan D, Hassell A, Dickerson SH, et al. A unique structure for epidermal growth factor receptor bound to GW572016 (Lapatinib): Relationships among protein conformation, inhibitor off-rate, and receptor activity in tumor cells. Cancer Res 2004;64: 6652-9.
    • (2004) Cancer Res , vol.64 , pp. 6652-6659
    • Wood, E.R.1    Truesdale, A.T.2    McDonald, O.B.3    Yuan, D.4    Hassell, A.5    Dickerson, S.H.6
  • 24
    • 23944476155 scopus 로고    scopus 로고
    • Phase I safety, pharmacokinetics, and clinical activity study of Lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas
    • Burris HA 3rd, Hurwitz HI, Dees EC, Dowlati A, Blackwell KL, O'Neil B, et al. Phase I safety, pharmacokinetics, and clinical activity study of Lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas. J Clin Oncol 2005;23:5305-13.
    • (2005) J Clin Oncol , vol.23 , pp. 5305-5313
    • Burris 3rd, H.A.1    Hurwitz, H.I.2    Dees, E.C.3    Dowlati, A.4    Blackwell, K.L.5    O'Neil, B.6
  • 25
    • 0030027934 scopus 로고    scopus 로고
    • Rees S, Coote J, Stables J, Goodson S, Harris S, Lee MG. Bicistronic vector for the creation of stable mammalian cell lines that predisposes all antibiotic-resistant cells to express recombinant protein. Biotechniques 1996;20:102-4, 106, 108-10.
    • Rees S, Coote J, Stables J, Goodson S, Harris S, Lee MG. Bicistronic vector for the creation of stable mammalian cell lines that predisposes all antibiotic-resistant cells to express recombinant protein. Biotechniques 1996;20:102-4, 106, 108-10.
  • 26
    • 0035874981 scopus 로고    scopus 로고
    • Trastuzumab (herceptin), a humanized anti-Her2 receptor monoclonal antibody, inhibits basal and activated Her2 ectodomain cleavage in breast cancer cells
    • Molina MA, Codony-Servat J, Albanell J, Rojo F, Arribas J, Baselga J. Trastuzumab (herceptin), a humanized anti-Her2 receptor monoclonal antibody, inhibits basal and activated Her2 ectodomain cleavage in breast cancer cells. Cancer Res 2001;61:4744-9.
    • (2001) Cancer Res , vol.61 , pp. 4744-4749
    • Molina, M.A.1    Codony-Servat, J.2    Albanell, J.3    Rojo, F.4    Arribas, J.5    Baselga, J.6
  • 27
    • 0034594628 scopus 로고    scopus 로고
    • New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada
    • Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205-16.
    • (2000) J Natl Cancer Inst , vol.92 , pp. 205-216
    • Therasse, P.1    Arbuck, S.G.2    Eisenhauer, E.A.3    Wanders, J.4    Kaplan, R.S.5    Rubinstein, L.6
  • 28
    • 0023733226 scopus 로고
    • Different structural alterations upregulate in vitro tyrosine kinase activity and transforming potency of the erbB-2 gene
    • Segatto O, King CR, Pierce JH, Di Fiore PP, Aaronson SA. Different structural alterations upregulate in vitro tyrosine kinase activity and transforming potency of the erbB-2 gene. Mol Cell Biol 1988;8:5570-4.
    • (1988) Mol Cell Biol , vol.8 , pp. 5570-5574
    • Segatto, O.1    King, C.R.2    Pierce, J.H.3    Di Fiore, P.P.4    Aaronson, S.A.5
  • 29
    • 0035888069 scopus 로고    scopus 로고
    • Truncated ErbB2 receptor enhances ErbB1 signaling and induces reversible, ERK-independent loss of epithelial morphology
    • Egeblad M, Mortensen OH, Jaattela M. Truncated ErbB2 receptor enhances ErbB1 signaling and induces reversible, ERK-independent loss of epithelial morphology. Int J Cancer 2001;94:185-91.
    • (2001) Int J Cancer , vol.94 , pp. 185-191
    • Egeblad, M.1    Mortensen, O.H.2    Jaattela, M.3
  • 30
    • 33744493376 scopus 로고    scopus 로고
    • Targeting tyrosine kinases in cancer: The second wave
    • Baselga J. Targeting tyrosine kinases in cancer: The second wave. Science 2006;312:1175-8.
    • (2006) Science , vol.312 , pp. 1175-1178
    • Baselga, J.1
  • 32
    • 0035169666 scopus 로고    scopus 로고
    • Mechanism of action of trastuzumab and scientific update
    • Baselga J, Albanell J, Molina MA, Arribas J. Mechanism of action of trastuzumab and scientific update. Semin Oncol 2001;28 Suppl 164-11.
    • (2001) Semin Oncol , vol.28 , Issue.SUPPL. , pp. 164-111
    • Baselga, J.1    Albanell, J.2    Molina, M.A.3    Arribas, J.4
  • 33
    • 0025964104 scopus 로고
    • The transforming potential of the c-erbB-2 protein is regulated by its autophosphorylation at the carboxyl-terminal domain
    • Akiyama T, Matsudal S, Namba Y, Saito T, Toyoshima K, Yamamoto T. The transforming potential of the c-erbB-2 protein is regulated by its autophosphorylation at the carboxyl-terminal domain. Mol Cell Biol 1991;11:833-42.
    • (1991) Mol Cell Biol , vol.11 , pp. 833-842
    • Akiyama, T.1    Matsudal, S.2    Namba, Y.3    Saito, T.4    Toyoshima, K.5    Yamamoto, T.6
  • 35
    • 33751416678 scopus 로고    scopus 로고
    • HKI-272, an irreversible pan erbB receptor tyrosine kinase inhibitor: Preliminary phase 1 results in patients with solid tumors
    • ABstract
    • Wong KK, Fracasso PM, Bukowski RM, Munster PN, Lynch T, Abbas R, et al. HKI-272, an irreversible pan erbB receptor tyrosine kinase inhibitor: preliminary phase 1 results in patients with solid tumors. Proc Am Soc Clin Oncol 2006;24:ABstract 3018.
    • (2006) Proc Am Soc Clin Oncol , vol.24 , pp. 3018
    • Wong, K.K.1    Fracasso, P.M.2    Bukowski, R.M.3    Munster, P.N.4    Lynch, T.5    Abbas, R.6
  • 36
    • 33745574028 scopus 로고    scopus 로고
    • Early tumor response to Hsp90 therapy using HER-2 PET: Comparison with 18F-FDG PET
    • Smith-Jones PM, Solit D, Afroze F, Rosen N, Larson SM. Early tumor response to Hsp90 therapy using HER-2 PET: Comparison with 18F-FDG PET. J. Nucl Med 2006;47:793-6.
    • (2006) J. Nucl Med , vol.47 , pp. 793-796
    • Smith-Jones, P.M.1    Solit, D.2    Afroze, F.3    Rosen, N.4    Larson, S.M.5
  • 38
    • 0027468645 scopus 로고
    • A truncated intracellular HER-2/neu receptor produced by alternative RNA processing affects growth of human carcinoma cells
    • Scott GK, Robles R, Park JW, Montgomery PA, Daniel J, Holmes WE, et al. A truncated intracellular HER-2/neu receptor produced by alternative RNA processing affects growth of human carcinoma cells. Mol Cell Biol 1993;13:2247-57.
    • (1993) Mol Cell Biol , vol.13 , pp. 2247-2257
    • Scott, G.K.1    Robles, R.2    Park, J.W.3    Montgomery, P.A.4    Daniel, J.5    Holmes, W.E.6


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.